Nature1 个月
Sodium channel blocker reduces skin inflammation
Benzamil (the benzyl derivative of the epithelial sodium channel blocker amiloride, a commonly used diuretic agent) showed a marked anticorrelation with psoriasis, which implicated down-regulation ...
Yale Daily News2 天
First FDA-approved non-addictive painkiller has Yale roots
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
NBC News on MSN9 天
FDA approves new type of nonopioid painkiller for acute pain
The signal is triggered by sodium rushing into the nerve ending, sending the message onward to the brain. Suzetrigine is a ...
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
Healio8 天
FDA approves nonopioid Journavx for moderate to severe acute pain
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
ScienceAlert2 天
New Non-Opioid Painkiller First in Decades to Win FDA Approval
A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first ...
Oncology Nurse Advisor3 天
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
First new non-opioid painkiller approved in the US for decades – here’s how it works
The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, ...